Ceska Gynekol. 2021;86(4):228-235. doi: 10.48095/cccg2021228.
Preeclampsia is a life-threatening condition for the mother and foetus. Globally, it is dia-gnosed in 10 mil. women every year, which accounts for 3% to 8% of all pregnancies. Currently there is no proven effective treatment for preeclampsia. The aforesaid text actualises the issue of predicting this complication. To determine the prognostic significance of matrix metalloproteinases-2 and -9 levels as early markers of preeclampsia, the present prospective study was conducted.
The levels of matrix metalloproteinases-2 and -9 were assessed in 72 patients. Thirty-four of them subsequently developed preeclampsia during pregnancy (20 patients with moderate preeclampsia, 14 patients with severe preeclampsia), and constituted the basic group; 38 patients made up the control group.
In pregnant women with the subsequent development of preeclampsia, the level of matrix metalloproteinase-2 at 11-13 weeks of gestation was 155 ± 73.4 ng/mL and significantly exceeded its level in pregnant women without hypertensive disorders - 75.0 ± 32.8 ng/mL. The study conducted demonstrates a significantly lower concentration of matrix metalloproteinase-9 in pregnant women with preeclampsia compared to the control - 749 ± 296 ng/mL and 1,667 ± 552 ng/mL (P < 0.001). The performed research figures that in the first trimester, the cut-off value of matrix metalloproteinase-2 for predicting the development of preeclampsia is 102 ng/mL (sensitivity 88.24% and specificity 82.76%). For matrix metalloproteinase-9, a level of 980 ng/mL in the first trimester predicts the development of preeclampsia with a sensitivity of 85.29% and a specificity of 84.48%.
The study established the cut-off values of matrix metalloproteinases-2 and -9 for predicting the development of preeclampsia in the first trimester.
子痫前期是一种危及母婴生命的疾病。全球范围内，每年有 1000 万名妇女被诊断出患有这种疾病，占所有妊娠的 3%至 8%。目前，子痫前期尚无有效的治疗方法。上述文本探讨了预测这种并发症的问题。为了确定基质金属蛋白酶-2 和 -9 水平作为子痫前期早期标志物的预测意义，本前瞻性研究进行了评估。
评估了 72 名患者的基质金属蛋白酶-2 和 -9 水平。其中 34 名患者在怀孕期间随后发展为子痫前期（20 名患者为中度子痫前期，14 名患者为重度子痫前期），构成基础组；38 名患者构成对照组。
在随后发展为子痫前期的孕妇中，在 11-13 周妊娠时基质金属蛋白酶-2 水平为 155 ± 73.4ng/mL，明显高于无高血压疾病的孕妇水平-75.0 ± 32.8ng/mL。本研究表明，子痫前期孕妇基质金属蛋白酶-9 的浓度明显低于对照组-749 ± 296ng/mL 和 1667 ± 552ng/mL（P < 0.001）。研究结果表明，在孕早期，基质金属蛋白酶-2 预测子痫前期发生的截断值为 102ng/mL（敏感性 88.24%，特异性 82.76%）。对于基质金属蛋白酶-9，孕早期水平为 980ng/mL 可预测子痫前期的发生，敏感性为 85.29%，特异性为 84.48%。
本研究确定了基质金属蛋白酶-2 和 -9 在孕早期预测子痫前期发生的截断值。
